Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GrB-Fc-HMEL
- Development stage
- Preclinical
- Lead developer
- AbBC Therapies
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GrB-Fc-HMEL is a preclinical-stage recombinant fusion protein developed by AbBC Therapies. It is part of the company's Targeted Granzyme B Immunotherapy (TGI) platform and consists of human Granzyme B fused to an Fc domain and a targeting moiety specific for Chondroitin Sulfate Proteoglycan 4 (CSPG4), also known as Melanoma-Associated Chondroitin Sulfate Proteoglycan (MCSP). The therapeutic mechanism involves the specific binding of the fusion protein to CSPG4-expressing tumor cells, followed by internalization and the delivery of Granzyme B into the cytosol. Once inside the cell, Granzyme B triggers the apoptotic pathway, leading to targeted cell death. This agent is being investigated for the treatment of various CSPG4-positive malignancies, including melanoma, triple-negative breast cancer (TNBC), lobular breast cancer, gliomas, and squamous cell carcinomas.
- Other names
- Granzyme B–Fc fusion proteinGrB-Fc-CSPG4GrB-Fc-CSPG-4GrB-Fc-CSPG 4
02
Targets
CSPG4 (Chondroitin sulfate proteoglycan 4)GZMB (Granzyme B)
Beyond the preview
Go deeper on GrB-Fc-HMEL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GrB-Fc-HMEL.